Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.

Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, TX, will present Phase 2 results demonstrating perifosine's single agent efficacy in patients with metastatic renal cell carcinoma on Saturday, September 26th at 10:00 am CST, in a presentation entitled " Phase 2 study of perifosine in patients with metastatic renal cell carcinoma progressing after prior therapy with both a VEGF Receptor Inhibitor and an mTOR inhibitor."

This multi-center Phase 2 study was led by both Dr. Hutson and Dr. Nicholas Vogelzang, Chair and Medical Director of Developmental Therapeutics, Comprehensive Cancer Centers of Nevada / US Oncology Research. Drs. Hutson and Vogelzang also serve as co-chairs of the Genitourinary Committee for US Oncology Research. Data from this study was first presented by Dr. Vogelzang at the ASCO meeting in May 2009. Dr. Hutson's presentation will include updated information from the study.

About Renal Cell Carcinoma (RCC)

Of all kidney tumors, 85% are classified as renal cell carcinoma (RCC) and of all patients with RCC, 25% present with advanced disease. Advanced RCC is resistant to such standard treatments as radiation therapy and chemotherapy, and the initial treatment for most patients is surgical removal of the kidney. If the cancer is confined to th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , NATICK, Mass. and LONDON, Nov. 20 /P...ion (NYSE: BSX ) today announced that it has rec... Administration (FDA) and CE Mark approval to mark...nt for the treatment of malignant esophageal stric...with resectable or non-resectable esophageal cance...
(Date:11/20/2009)..., , HOUSTON, Nov. 20 /PRNewswire-FirstC...nounced that Dan Moore, President and Chief Execut...cer, will present at the 21st Annual Piper Jaffray...December 2, 2009 at 12:00 PM EST. The conference ...al slides will be presented. Piper Jaffray will h...
(Date:11/20/2009)..., , FRANKLIN LAKES, N.J., Nov. 20 /PRNewsw...y) (NYSE: BDX ) today announced the completion o... Michigan-based company that develops and manufact...atforms. ,, In May 2009, BD and HandyLab announ...ommercialize molecular assays on the HandyLab Jagu...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Drug Might Restore Sense of Smell 51357 1Drug Might Restore Sense of Smell 51357 2Drug Might Restore Sense of Smell 51357 3Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 1Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 2New Poll Shows Americans Continuing to Move Toward Pro Life Position on Abortion 51348 1New Poll Shows Americans Continuing to Move Toward Pro Life Position on Abortion 51348 2
...7 The Department of,Justice announced today that ...e on Cancer (CRC) to develop and publicize model c...new cancer treatments. The Department said,the lan...be used to help,increase efficiency in contract ne...ing the time needed to begin clinical trials., Th...
...pt. 17 Sanofi pasteur, the,vaccines division of t...s,sponsoring a Phase II clinical study exploring a... advanced-stage melanoma -- an often fatal form of...ons. Patients are being,enrolled in the United Sta...stigate the safety and efficacy of a therapeutic c...
Other Medicine Technology:Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 2Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 4Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 5
(Date:11/20/2009)...swire-USNewswire/ -- The United States Conference ...tial changes its health reform bill in order to ke...nscience protection on abortion, protect access to...visions for adequate affordability. ,, The bish...s disappointment" that creates new and unacceptabl...
(Date:11/20/2009)...wswire-FirstCall/ -- Rates of infection by the 200...ober, but the pandemic flu virus continues to be a...cluding the elderly, according to a new report by ... world,s leading provider of diagnostic testing, i... Quest Diagnostics Health Trends(TM) Report "Testi...
(Date:11/20/2009)...20 Cardio Vascular,Medic....COM , a leading,developer of advanced cardiovascu...ompany,s Board of Directors has decided to initiat...r East for its proprietary next-generation,"steera...A) procedures. , Cardio Vascular Medical ...
(Date:11/20/2009)...ire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI... Radio Reports: What Every Women Needs to Know Ab...eran journalist Perri Peltz. ,, (Logo: http:/... ) ,, Doctor Radio Reports: What Every Woman...er 21 live at 10:00 am ET on Doctor Radio , SIRIU...
(Date:11/20/2009)... with chronic kidney disease often fail to detect ...increasing a child,s risk for serious heart proble...ren,s Center and other institutions. A report of t...can Society of Nephrology. , Researchers compa...gular doctor visits to readings obtained via a spe...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:High blood pressure easy to miss in children with kidney disease 2
...mber 11, 2007 Takeda Pharmaceuticals North Americ...one HCl) data conducted by A. Michael Lincoff, M.D...ed in the Journal of the American Medical Associat...tients with diabetes versus control therapy. , ...
...ostate biopsies resulted in a cancer diagnosis amo...e first biopsy did not find cancer often had multi...ance of a cancer diagnosis. , While PSA (prostat...Nonetheless, it remains unclear whether or not PSA...
...n now have another good reason to consider taking ...s an enlarged prostate and reduces the risk of get...om the Southwest Oncology Group strongly suggests ...ncers early, when they are most easily treatable. ...
...arker, not a cause, of renal trouble, study sugges...-- Lowering blood levels of an inflammation-linke...th serious kidney disease live any longer, new res...e who took extra folic acid, vitamin B6 and vitami...
...11 Dr. Walter,Cottrell, Pennsylvania Game Commiss...e test result from an adult female deer has confir...een found in Beaver County., "This outbreak of EH...dition, the fact that we are finding EHD earlier,t...
...s Conclude Sweetener Is Safe Across Population ...Sept. 11 A report published in the,September issu...sue 8, pp.,629-727) systematically evaluates virtu...of eight recognized scientists,from research insti...
Other Medicine News:Health News:Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association 2Health News:Other highlights in the September 11 JNCI 2Health News:Other highlights in the September 11 JNCI 3Health News:Generic prostate drug helps find high-risk cancers early 2Health News:Generic prostate drug helps find high-risk cancers early 3Health News:Lowering Blood Protein Won't Help Kidney Patients 2Health News:Lowering Blood Protein Won't Help Kidney Patients 3Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 2Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 3Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 4Health News:New Expert Report Dispels Common Myths About Aspartame 2Health News:New Expert Report Dispels Common Myths About Aspartame 3
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: